Kevin Moore, MD
Family Medicine · Bardstown, KYNPI 1740270016
Payments from drug & device makers
Across 187 payments — averaging $15.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$386
- Novo Nordisk$383
- Pfizer$382
- Lilly USA, LLC$304
- GSK$224
- Amgen$170
- plus $1K from 24 others
What the payments were for
- Food & beverage$2,868100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 22 | $386 |
| Novo Nordisk | 28 | $383 |
| Pfizer | 27 | $382 |
| Lilly USA, LLC | 20 | $304 |
| GSK | 16 | $224 |
| Amgen | 10 | $170 |
| AstraZeneca | 11 | $167 |
| Boehringer Ingelheim | 8 | $124 |
| Sanofi-aventis U.S. LLC | 7 | $89 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $77 |
| Novartis | 4 | $69 |
| Exact Sciences | 4 | $57 |
| Astellas Pharma US Inc | 3 | $48 |
| Merck | 3 | $39 |
| Xeris Pharmaceuticals, Inc. | 2 | $38 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $33 |
| Corcept Therapeutics | 2 | $32 |
| Amarin Pharma, Inc. | 2 | $29 |
| Boston Scientific | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Hologic Sales And Service, LLC | 1 | $21 |
| Dermira, Inc. | 1 | $18 |
| Vertos Medical, Inc. | 1 | $18 |
| Bayer | 1 | $17 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Inspire Medical Systems, Inc. | 1 | $14 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Si-bone, Inc. | 1 | $11 |
How this compares
$2,868 in reported general payments places this provider in the 75th percentile of 1,559 family medicine providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 209 | $203,020 |
| OzempicSemaglutide | 98 | $170,433 |
| JardianceEmpagliflozin | 69 | $96,687 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 64 | $70,267 |
| TrulicityDulaglutide | 38 | $62,974 |
| FarxigaDapagliflozin Propanediol | 36 | $39,748 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $28,840 |
| Repatha SureclickEvolocumab | 20 | $25,960 |
| MyrbetriqMirabegron | 34 | $23,419 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 15 | $22,416 |
| Spiriva RespimatTiotropium Bromide | 20 | $18,810 |
| Breo ElliptaFluticasone/Vilanterol | 25 | $17,377 |
| XareltoRivaroxaban | 15 | $17,053 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $16,348 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 50 | $13,561 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $382 | $203,020209 claims |
| Novo NordiskOzempic | $383 | $170,43398 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Stiolto Respimat | $124 | $127,868107 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $224 | $95,414101 claims |
| Lilly USA, LLCTrulicity | $304 | $62,97438 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $167 | $56,09652 claims |
| Astellas Pharma US IncMyrbetriq | $48 | $23,41934 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $89 | $22,41615 claims |
| AbbVieSynthroid | $386 | $2,81060 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,559 family medicine providers in Kentucky.
Other family medicine in Bardstown
- Brian SmithVersailles$7.7M
- Barbara Fleming-PhillipsLexington$1.4M
- Christopher RhyneLouisville$1M
- Kruti PatelBurlington$463K
- Michael LovelaceLouisville$244K
- John RichardLexington$226K
- Diego MastronardiBowling Green$196K
- James TurnboPaducah$124K
- Eleida Tur OlivaLexington$113K
- Jeffrey GreenParis$103K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.